Clinical Trial Update: Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) [Phase 2]

View source ↗

Summary

Phase 2 trial update for mavrilimumab in severe COVID-19 pneumonia with hyperinflammation (COMBAT-19) is ongoing; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mavrilimumab (mavrilimumab)

Snippet

Sponsor: Ospedale San Raffaele | Conditions: Covid-19, Acute Respiratory Failure | Phase 2 | Status: UNKNOWN